EcoDrugPlus

Aldose Reductase-Like

Ensembl ID : ENSAOCG00000016758
Gene Symbol: LOC111563385
3 Cross references
348 Possible Orthologues:

Aldose Reductase-Like

Ensembl ID : ENSAOCG00000016808
Gene Symbol: LOC111563677
3 Cross references
350 Possible Orthologues:

Alpha-1a Adrenergic Receptor

Ensembl ID : ENSAOCG00000019734
Gene Symbol: LOC111580378
3 Cross references
202 Possible Orthologues:

Alpha-1a Adrenergic Receptor-Like

Ensembl ID : ENSAOCG00000011993
Gene Symbol: LOC111573441
3 Cross references
192 Possible Orthologues:

Alpha-2b Adrenergic Receptor-Like

Ensembl ID : ENSAOCG00000017504
Gene Symbol: LOC111564716
3 Cross references
175 Possible Orthologues:

Alpha-2c Adrenergic Receptor-Like

Ensembl ID : ENSAOCG00000022095
Gene Symbol: LOC111576733
3 Cross references
162 Possible Orthologues:

Alpha-Synuclein-Like

Ensembl ID : ENSAOCG00000004451
Gene Symbol: LOC111585205
2 Cross references
189 Possible Orthologues:

Amine Oxidase Copper Containing 1

Ensembl ID : ENSAOCG00000015706
Gene Symbol: AOC1
3 Cross references
233 Possible Orthologues:

Amyloid Beta Precursor Protein

Ensembl ID : ENSAOCG00000006353
Gene Symbol: APP
4 Cross references
206 Possible Orthologues:

Amyloid-Beta A4 Protein-Like

Ensembl ID : ENSAOCG00000015844
Gene Symbol: LOC111568091
3 Cross references
205 Possible Orthologues:

Androgen Receptor

Ensembl ID : ENSAOCG00000017118
Gene Symbol: AR
2 Cross references
214 Possible Orthologues:

Angiotensin Ii Receptor Type 1

Ensembl ID : ENSAOCG00000018875
Gene Symbol: AGTR1
3 Cross references
203 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).